At present, the penetration rate of China's ICL industry is only 6%, far behind Japan's 60% and the United States' 35%. In 2021, the market size of China's ICL industry (excluding COVID-19 testing) was 22.3 billion yuan. In the future, with the improvement of industry penetration and the promotion of national policies, it is expected that the market size will increase to 51.3 billion yuan by 2026, with an average annual growth rate of 18%. There is no cost advantage in conducting special testing programs in hospitals, so the demand for outsourcing will continue to rise. In this case, the special testing market is expected to usher in new development opportunities. According to **, China's ICL special testing market space will grow from 10.3 billion yuan in 2021 to 28.9 billion yuan in 2026, with an average annual growth rate of 23%, showing a trend of rapid development.
It shows a strong momentum for sustainable development
As a pioneer in the ICL field, Golden Mile Medical is a leader in terms of laboratory facilities, coverage area, and number of customers. At present, the company has 49 central laboratories, covering more than 90% of the country's population. Jinyu Medical provides more than 3,900 test items, which not only meet the routine testing needs of hospitals, but also focus on innovation, covering diverse clinical precision diagnosis needs.
In addition, Jinyu Medical works closely with large tertiary hospitals or scientific research institutes to carry out joint scientific and technological research projects, and has established more than 190 partnerships. These partners include well-known medical institutions and research institutes, and are jointly committed to promoting scientific and technological innovation and R&D in the field of medicine. Through close cooperation with these partners, Jinyu Medical is able to make full use of the professional knowledge and resources of all parties to carry out research and application of cutting-edge technologies to further improve the quality and efficiency of medical examination services. This continuous partnership provides a broader development platform for Jinyu Medicine, and also makes a positive contribution to innovation and progress in the field of medicine.
Significant progress has been made in several medical fields
The latest data report shows that Jinyu Medical has performed well in key key diseases, especially in the diagnosis of infectious diseases, with business growth of up to 513%。In addition, growth was achieved in the areas of genetic and rare diseases, neurological and psychiatric diseases, and cardiovascular and endocrine disease diagnosis, respectively. 36%。Jinyu Medical has carried out independent innovation and research and development in these fields, and has launched a series of special projects, such as upgraded RNA-Seq detection, tumor whole transcriptome (WTS) sequencing detection and Alzheimer's disease early screening detection, etc., which have been widely recognized by the clinical community.
At the same time, Jinyu Medical has also made significant progress in further optimizing its customer structure. **The proportion of hospital revenue increased to 4265%, an increase of 587 percentage points. This optimization not only has a driving effect on business growth, but also makes Jinyu Medical's business growth more sustainable.
Actively promote digital transformation to move towards smart medical testing
Passed the "Medical Examination 40"With the continuous deepening of digital transformation, Jinyu Medical has established a digital team composed of more than 200 professionals, focusing on three major technical capabilities: computer vision, natural language knowledge graph and multimodal and multi-omics. In the first half of 2023 alone, the company has introduced nearly 250 master's and doctoral talents, covering key areas such as clinical consulting, digitalization, R&D, and laboratory technology.
With years of deep cultivation in the field of medical testing, the total number of tests of Jinyu Medical has exceeded 2.5 billion, and the data volume has exceeded 10PB, and has successfully established the world's leading large sample bank and database of oriental ethnicity. These data resources provide a solid foundation for digital transformation and accelerate the development and application of large samples and big data in clinical research, medical laboratory technology innovation, and artificial intelligence.
In the future, Jinyu Medical will continue to devote itself to innovation and leadership, transform more innovative achievements into practical results that can be implemented, promoted and valuable, and continuously inject new impetus into the high-quality development of the field of medical diagnostic services. In the context of the continuous integration of biotechnology and new information technology, Jinyu Medical is expected to bring more innovations and breakthroughs in the field and promote the progress of medical diagnostic services.